Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
ClinicalTrials.gov serves as the primary registry for finding active studies
The Centers for Medicare and Medicaid Services announced the Medicare GLP-1 Bridge in May 2026, confirming that eligible Part D enrollees will be able to access certain GLP-1 drugs including the obesity-specific formulations of semaglutide (Wegovy) and tirzepatide (Zepbound) for a fixed cost of $50 per month through December 2027
If youre considering AOD-9604 therapy, schedule a consultation with our medical team to discuss your health history, body composition goals, and whether this research peptide aligns with your metabolic optimization objectives under proper medical supervision
References Frias JP, Bonora E, Ruiz RG, et al
The population of Americans age 65 and older is projected to grow from 65 million in 2026 to 82 million by 2050
Compliance with ethics requirements We have obtained informed consent from all participants, and all processes involving human tissues in this study were approved by the Ethics Committee of the First Affiliated Hospital of Jinan University (approval number: KY-2021-092)
US$ 21.32
US$ 22.31
US$ 28.64
US$ 27.80
US$ 24.24
US$ 28.51
